StockData

Amylyx Pharmaceuticals vs Zevra Therapeutics

AMLX and ZVRA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How AMLX and ZVRA compare

Amylyx Pharmaceuticals is the larger company, worth 5.5 times as much as Zevra Therapeutics ($3.1B against $558M).

Zevra Therapeutics scores higher on the StockData Score (15 against 6 for Amylyx Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricAMLXZVRA
Size and price
Market cap$3.1B$558M
Share price$27.52$9.40
Change, 1 year117%5.9%
Change, 5 years168%16.8%
Beta (5Y)0.541.16
Employees13661
StockData Score
Total score615 (better)
Valuation score03 (better)
Growth score03 (better)
Performance score03 (better)
Health score66
Dividend score00
Valuation
P/E–10.1×
P/S–4.1×
P/B12.8×2.6× (better)
EV/EBITDA–4.0×
P/FCF–17.1×
FCF yield–5.8%
Fair value–$23.57
Margin of safety–60.1%
Growth
Revenue growth (TTM)–119%
Revenue growth, 5Y average–51.6%
Net income growth (TTM)–2104%
Profitability
Gross margin–95.5%
Operating margin–60.5%
Net margin–42.8%
FCF margin–24.0%
Return on equity−74.7%34.8% (better)
Financial health
Debt / equity0.000.00
Net debt / EBITDA–−2.64
Interest coverage–14.4×
Current ratio12.12 (better)5.17
Altman Z-score67.06 (better)4.35
Piotroski F-score46 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions104%78.5%
Held by insiders7.8%1.2%
Insider net buying, 12 months−$17.2M−$2.5M (better)
Short interest, % of float12.5%11.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.